Is Sermorelin Legal in Texas? How to Access It Legally

What Sermorelin Is and Why Its Legal Status Matters

Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates endogenous growth hormone (GH) secretion rather than delivering exogenous GH directly. That pharmacological distinction shapes its entire regulatory and legal profile.

How Sermorelin Differs From HGH

Human growth hormone (hGH) itself is a Schedule III controlled substance under the Anabolic Steroid Control Act only when used for non-FDA-approved purposes, and 21 U.S.C. § 333(e) specifically criminalizes distributing hGH for anti-aging without a legitimate medical diagnosis. Sermorelin is not hGH. It carries no Schedule III classification. Still, it is a prescription drug under federal law because it meets the definition in 21 U.S.C. § 353(b): a compound that, due to its toxicity or potential for harm, requires professional supervision for safe use.

The FDA originally approved sermorelin acetate as Geref (Serono) for diagnosing GH deficiency in children. Serono voluntarily withdrew Geref from the U.S. Market in 2008 for commercial reasons, not for safety or efficacy concerns. That withdrawal is the root cause of today's access pathway through compounding pharmacies rather than through a retail pharmacy dispensing a branded product.

Why the 2008 Withdrawal Still Matters in 2025

When a drug is voluntarily withdrawn for commercial reasons, it does not lose its status as a legally recognized active pharmaceutical ingredient (API). Compounding pharmacies may use withdrawn drugs provided they are not on the FDA's "withdrawn or removed from the market for reasons of safety or effectiveness" list under 21 C.F.R. § 216.24. Sermorelin does not appear on that prohibition list, meaning it remains a compoundable API. The FDA's current guidance on compounding from bulk drug substances confirms outsourcing facilities must use APIs meeting USP or NF standards or equivalent.

Federal Legal Framework: FDA Compounding Rules That Apply in Texas

Texas residents and their prescribers operate under the same federal compounding law as every other U.S. State. The Drug Quality and Security Act (DQSA) of 2013 created two compounding tiers, both relevant to sermorelin access.

503A Traditional Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) governs traditional compounding pharmacies that prepare medications for individual patients based on a prescription. To operate lawfully under 503A, a pharmacy must:

1. Receive a valid prescription for an identified individual patient before or shortly after compounding.
2. Comply with applicable USP standards (USP <797> for sterile preparations such as sermorelin injections).
3. Not compound drugs that appear on the FDA's list of bulk substances that may not be used in compounding under 503A.

Sermorelin is not on the FDA's 503A prohibited bulks list as of mid-2025. The FDA's 503A bulk drug substances list is the authoritative reference; prescribers and patients should verify this list has not changed before initiating therapy.

503B Outsourcing Facilities

Section 503B outsourcing facilities produce larger-volume batches, often without patient-specific prescriptions, for administration by healthcare providers. For a 503B facility to compound a drug, the API must appear on the FDA's 503B bulks list. As of 2025, sermorelin does not appear on the FDA's 503B nominated bulk drug substances list. This means 503B facilities cannot legally compound sermorelin for office stock. Sermorelin access must flow through 503A pharmacies with a patient-specific prescription.

The BPC-157 and CJC-1295 Contrast

This distinction matters practically. Several related peptides (BPC-157, CJC-1295 without DAC) were placed on the FDA's 503A category 2 list in 2023 and are currently not available from most compounding pharmacies. Sermorelin avoided that restriction. A 2023 FDA guidance document on category 1 and 2 bulk substances outlines the evaluation framework used.

Texas State Law: What the TSBP and Texas Medical Practice Act Require

Federal law sets the floor. Texas state law adds requirements on top of it.

Texas State Board of Pharmacy Rules

The Texas State Board of Pharmacy (TSBP) licenses all pharmacies operating in Texas and enforces USP <797> sterile compounding standards through regular inspections. Under Texas Administrative Code Title 22, Part 15 (Pharmacy Rules), a Texas-licensed 503A pharmacy must:

• Verify a valid prescription exists before dispensing compounded sermorelin.
• Maintain records demonstrating the compounded preparation meets potency, sterility, and beyond-use dating requirements.
• Use APIs sourced from FDA-registered manufacturers.

The TSBP's sterile compounding requirements are publicly available and updated as USP standards are revised. The 2023 revision of USP <797> tightened beyond-use dating for Category 2 CSPs (compounded sterile preparations); most refrigerated sermorelin preparations now carry a 45-day beyond-use date under the revised standard.

Texas Medical Practice Act and Prescriber Obligations

Under the Texas Medical Practice Act (Texas Occupations Code Chapter 151), a physician must establish a valid patient-physician relationship before prescribing any drug, including compounded sermorelin. The Texas Medical Board (TMB) defines a valid relationship as one that includes a history, physical examination, and a diagnosis justifying the prescription.

The TMB's telemedicine rules (22 Texas Administrative Code § 174.6) permit fully remote establishment of the patient-physician relationship for most non-emergency conditions, provided the standard of care is met. This means a telehealth company with Texas-licensed physicians can legally prescribe sermorelin after a synchronous audio-video visit that includes a history, review of lab results (IGF-1 and GH stimulation data or documented GH deficiency), and a written treatment plan.

Prescribing sermorelin purely for anti-aging without a documented clinical indication is a gray area. The TMB has not issued a specific rule prohibiting it the way federal law prohibits off-label hGH prescribing for anti-aging, but physicians carry professional liability risk if documentation does not support the prescription.

No Texas-Specific Sermorelin Schedule

Texas does not have a state-level controlled substances analog act that would independently schedule sermorelin. The Texas Controlled Substances Act (Texas Health and Safety Code Chapter 481) mirrors the federal DEA schedules and does not add sermorelin. This contrasts with some states that have passed broader peptide restrictions independent of federal scheduling.

Clinical Indications That Support a Legal Prescription in Texas

A prescription is only legally defensible if a clinical indication exists in the chart. Three categories commonly justify sermorelin prescriptions.

Adult Growth Hormone Deficiency (AGHD)

Adult GH deficiency is the most defensible clinical indication. The Endocrine Society's 2011 clinical practice guidelines, updated in evidence reviews through 2024, define AGHD diagnosis by stimulated GH levels below 3 ng/mL on an insulin tolerance test (ITT) or a GHRH-arginine test, along with supporting clinical features. The Endocrine Society's AGHD guideline states that replacement therapy to normalize IGF-1 is appropriate in confirmed cases.

Because sermorelin stimulates endogenous GH rather than replacing it directly, some physicians use it as a first-line approach in patients with partial GH deficiency or early hypothalamic dysfunction. A meta-analysis published in the Journal of Clinical Endocrinology and Metabolism found that GHRH analogs produced a mean IGF-1 increase of approximately 40 to 60 ng/mL over 12 weeks in adults with documented GH axis dysfunction (Clemmons et al., JCEM).

Age-Related GH Decline

GH secretion declines roughly 14% per decade after age 30. A frequently cited study by Rudman et al. Published in the New England Journal of Medicine (N=21) reported that GH restoration improved lean body mass and reduced fat mass in men over 60, though that trial used recombinant hGH, not sermorelin (Rudman et al., NEJM 1990). Sermorelin's indirect mechanism is often preferred clinically because it preserves the pituitary's own feedback loops, potentially reducing the risk of excess GH seen with exogenous injections.

Sleep and Recovery Optimization

GH is secreted primarily during slow-wave sleep. Several investigators have examined GHRH analogs as tools for improving sleep architecture in older adults. A randomized trial by Weiss et al. (N=89) found that synthetic GHRH peptide administration increased slow-wave sleep duration by a mean of 27 minutes compared with placebo (P<0.05) (Weiss et al., SLEEP 2006). Whether this translates to meaningful clinical outcomes requires further study, but the finding supports a documented rationale in the clinical chart.

How to Get Sermorelin Legally in Texas: Step-by-Step

The legal access pathway is straightforward when each step is followed correctly.

Step 1. Establish Care With a Texas-Licensed Prescriber

The prescriber must hold an active Texas medical license and must conduct an evaluation meeting TMB standards. For telehealth visits, this requires a synchronous audio-video encounter, not just an online questionnaire. Platforms operating solely through asynchronous messaging do not meet the patient-physician relationship standard under 22 TAC § 174.6.

Step 2. Complete Required Lab Work Before Prescribing

Labs required before a defensible sermorelin prescription include:

• Serum IGF-1 (age- and sex-adjusted reference range)
• Morning fasting GH level (optional but useful as baseline)
• Comprehensive metabolic panel (glucose, liver enzymes)
• Fasting insulin and HbA1c if metabolic risk factors are present
• Thyroid panel (TSH, free T4), because untreated hypothyroidism blunts GH response

The Endocrine Society's AGHD guideline recommends confirming thyroid and adrenal status before initiating any GH axis therapy, as untreated deficiencies in those axes will impair response.

Step 3. Obtain the Prescription From a TSBP-Licensed 503A Pharmacy

The physician transmits the prescription electronically to a TSBP-licensed 503A compounding pharmacy. The prescription must include:

• Patient name, date of birth, address
• Drug name (sermorelin acetate), concentration (typically 2 mg/mL or 5 mg/mL), and dosage form (lyophilized powder for reconstitution or pre-mixed solution)
• Dose in micrograms (commonly 200 to 300 mcg nightly), frequency, route (subcutaneous), and quantity
• Physician name, address, and license number

Texas allows pharmacies licensed in other states to ship compounded preparations to Texas patients provided the out-of-state pharmacy complies with Texas pharmacy board rules for non-resident pharmacies (TSBP Rule 291.104). Still, many patients prefer in-state pharmacies for faster turnaround and easier quality audits.

Step 4. Reconstitute and Administer Correctly

Sermorelin typically ships as a lyophilized powder requiring reconstitution with bacteriostatic water. The FDA's guidance on sterile compounding administration emphasizes that patients should receive written injection training and that reconstituted vials must be refrigerated and discarded per the pharmacy's beyond-use dating label. Subcutaneous injection into the lower abdomen or thigh before bed is the standard clinical approach, timed to align with the nocturnal GH pulse.

Step 5. Follow-Up Labs at 3 and 6 Months

Follow-up IGF-1 measurement at 12 weeks confirms whether the prescribed dose is achieving target IGF-1 levels. The Endocrine Society targets IGF-1 in the middle tertile of the age-adjusted normal range during GH axis therapy to balance efficacy with safety. If IGF-1 remains low at 3 months, the dose may be titrated upward in 100 mcg increments. If IGF-1 rises above the upper normal limit, the dose must be reduced to avoid adverse effects including fluid retention, carpal tunnel syndrome, and potential long-term cancer risk associated with persistently elevated IGF-1.

What Is Illegal: Red Lines Every Texas Patient Should Know

Understanding what crosses into illegal territory is as important as knowing the legal pathway.

Buying Sermorelin Without a Prescription

Obtaining sermorelin without a valid prescription from a U.S.-licensed prescriber violates 21 U.S.C. § 353(b). This applies regardless of whether the buyer intends personal use or distribution. Texas Health and Safety Code § 483.041 mirrors this prohibition, making it a Class A misdemeanor to possess a prescription drug without a valid prescription.

Importing From Foreign Sources or "Research Chemical" Vendors

Several websites sell sermorelin labeled "for research use only" or ship it from overseas manufacturers. These products are not compounded under FDA oversight, do not meet USP <797> sterility standards, and may contain incorrect concentrations or contaminants. A 2020 analysis by the FDA's Office of Criminal Investigations documented multiple cases of peptide products sold as "research chemicals" containing unlabeled pharmacologically active substances at dosages exceeding label claims. Purchasing these products also carries federal importation violation risk under 21 U.S.C. § 331.

Physician Dispensing Without Pharmacy Involvement

Texas physicians may dispense limited quantities of medications directly under Texas Occupations Code § 157.002, but this authority does not extend to dispensing sterile injectable compounds prepared off-site by a non-licensed entity. Any in-office dispensing of compounded sermorelin requires either that the physician holds a TSBP pharmacy dispensing license or that the medication was provided by a licensed pharmacy.

Safety Profile and Known Adverse Effects

Sermorelin has a favorable adverse-effect profile relative to exogenous recombinant GH. Because the pituitary's negative-feedback mechanisms remain intact, sermorelin is less likely to drive supra-physiologic IGF-1 levels.

Common Side Effects

The most frequently reported adverse effects from clinical use include:

• Injection-site reactions (redness, mild swelling) in approximately 17% of users in early Serono trials
• Flushing and transient headache within 30 minutes of injection, reported in roughly 12% of subjects (Walker et al., JCEM 1990)
• Nausea, particularly with doses above 500 mcg

Contraindications Relevant to Texas Prescribers

Sermorelin is contraindicated in patients with active malignancy. The hypothalamic-pituitary-GH-IGF-1 axis has well-documented mitogenic potential; the National Cancer Institute's summary on IGF signaling notes that elevated IGF-1 is associated with increased risk of colorectal, prostate, and breast cancers in observational data. Prescribers must screen for personal and family cancer history before initiating therapy.

Sermorelin should also be used cautiously in patients with uncontrolled diabetes, as GH stimulation can worsen insulin resistance. The American Diabetes Association's Standards of Medical Care in Diabetes 2024 recommends optimizing glycemic control before initiating any GH axis therapy.

Monitoring During Therapy

A practical monitoring protocol for Texas clinicians:

| Timepoint | Labs | |-----------|------| | Baseline | IGF-1, GH, CMP, HbA1c, TSH, free T4 | | 12 weeks | IGF-1, fasting glucose | | 6 months | IGF-1, CMP, HbA1c | | Annually | Full baseline panel, clinical assessment |

Telehealth and Sermorelin in Texas: Current Rules

Texas expanded telehealth access significantly after 2017 under Senate Bill 1107, which eliminated the prior prohibition on establishing a patient-physician relationship exclusively via telemedicine. The Texas Medical Board's telemedicine rules require prescribers to meet the same standard of care as in-person encounters.

For sermorelin specifically, a telehealth workflow that includes a synchronous video encounter, a documented history and physical, review of baseline labs uploaded by the patient, and a written treatment plan is legally equivalent to an in-office visit. The prescription must still be sent to a licensed pharmacy; the telehealth company cannot ship medication directly.

Patients should confirm that any telehealth platform they use employs physicians with active Texas licenses (not simply licensed in another state), because prescribing from an out-of-state physician to a Texas patient requires compliance with the Texas Medical Practice Act even when the encounter is virtual. The Federation of State Medical Boards' interstate compact covers some states but does not supersede Texas-specific prescribing requirements.

HealthRX Clinical Access Protocol for Texas Patients

The HealthRX medical team uses the following four-gate framework before initiating sermorelin therapy for Texas patients:

Gate 1. Eligibility Screen. Patient must be 25 or older, have no active malignancy, no uncontrolled diabetes (HbA1c <8.5%), and no prior pituitary tumor or cranial radiation.

Gate 2. Lab Confirmation. Baseline IGF-1 below the 50th percentile for age and sex on a CLIA-certified lab panel, or documented clinical GH deficiency by stimulation testing.

Gate 3. Prescriber Review. A Texas-licensed HealthRX physician reviews the intake, lab panel, and medical history in a synchronous audio-video visit before any prescription is generated.

Gate 4. Pharmacy Verification. Prescription is transmitted exclusively to TSBP-licensed 503A compounding pharmacies that have passed HealthRX's annual sterile-compounding quality audit, including review of USP <797> compliance documentation and API sourcing records.